Market Overview

Gilead Sciences Rises After Q2 Report (GILD)

Gilead Sciences Rises After Q2 Report GILD
Related GILD
Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts
Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Bristol-Myers Looks Beyond Cancer To Build Portfolio (Investor's Business Daily)

Biotechnology giant Gilead Sciences (NASDAQ: GILD which has a market-cap approaching $100 billion, released its fiscal second quarter earnings results after the closing bell on Thursday.

The company reported adjusted earnings per share that was in-line with estimates and revenue that exceeded Wall Street expectations. In late trade, shares were last up almost 6 percent to $64.26.

Related:Find all of Thursday's stock movers in Benzinga's daily Market Wrap

Q2 Financial Results

Gilead reported net income of $772.6 million or $0.46 per share, compared to $711.6 million or $0.46 per share, in last year's second quarter.

On an adjusted basis, net income was $839.7 million or $0.50 per share, versus $767.3 million or $0.49 per share, in the year ago period. This was in-line with analysts' estimates.

Total revenue in the quarter was up 15 percent to $2.77 billion from $2.41 billion a year ago. This compared to analysts' consensus revenue estimates of $2.66 billion. Product sales rose 14 percent in the quarter to $2.66 billion from $2.32 billion last year.

Posted-In: Earnings News After-Hours Center Movers Best of Benzinga


Related Articles (GILD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters